Introduction Clopidogrel is metabolized by P450 (CYP)-isoenzymes: CYP 3A4/5, 1A2, 2B6, 2C9, and 2C19 1 Wide response variability and nonresponsiveness.

Slides:



Advertisements
Similar presentations
Resistance to Anti-Platelet Therapy in CAD Rabih R. Azar, MD, MSc, FACC Associate Professor of Medicine Director of Cardiovascular Research Division of.
Advertisements

Inhibitory Effects of Ticagrelor Compared to Clopidogrel on Platelet Function in Patients with Acute Coronary Syndromes The PLATO PLATELET Substudy Storey.
Paul Gurbel, Kevin Bliden, Tania Gesheff, Yvonne Kreutz, Udaya Tantry Sinai Center for Thrombosis Research Sinai Hospital of Baltimore Baltimore, Maryland,
Assessment of the best Loading dose of clopidogrel to Blunt platelet activation, Inflammation and Ongoing Necrosis ALBION.
Oral Antiplatelet Agents: A Cornerstone of Therapy for Atherothrombotic Disease Aspirin and clopidogrel: - Reduce the risks of myocardial infarction, ischemic.
Long-term Outcomes of Patients with ACS and Chronic Renal Insufficiency Undergoing PCI and being treated with Bivalirudin vs UFH/Enoxaparin plus a GP IIb/IIIa.
An Analysis of the ACUITY Trial Lincoff AM, JACC Intv 2008;1:639–48 Influence of Timing of Clopidogrel Treatment on the Efficacy and Safety of Bivalirudin.
A Risk Score for Predicting Coronary Artery Bypass Surgery in Patients with Non-ST Elevation Acute Coronary Syndromes Sai Sadanandan, MD*; Christopher.
STEMI Due to Stent Thrombosis: An Enlarging Subgroup of High Risk Patients Bruce Brodie, Adam Bensimhon, Nathan Fleishman, Charles Hansen, Mike Cooper,
Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Paul A. Gurbel, MD.
A significant proportion of diabetic patients develop diabetic nephropathy which can eventually progress to end-stage renal disease despite established.
Dose- and time-dependent antiplatelet effects of aspirin Christina Perneby, N. Håkan Wallén, Cathy Rooney, Desmond Fitzgerald, Paul Hjemdahl Published.
Jacqueline Saw, MD*, Danielle Brennan, MS †, Steven Steinhubl, MD ‡, Deepak L. Bhatt, MD †, Koon-Hou Mak, MD §, Keith Fox, MB^, and Eric J. Topol, MD #
Point of Care Platelet Function Testing – Is There Still Value?
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Clinical trial 2. Objective To evaluate efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention: Effects on Platelet Inhibition, Endothelial Function and Inflammation.
Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies.
The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the Plavix Response in Coronary Intervention (PRINC) trial ACTRN
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
Clinical Trial Results. org Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients with Diabetes Mellitus and Coronary Artery Disease:
(The CLEAR PLATELETS-2 Study) Bivalirudin With and Without Eptifibatide for Elective Stenting: A Pharmacodynamic Study of Platelet Reactivity in Relation.
* Based on post hoc analysis of individual outcome events (N=19,185). 1 Data on file, Sanofi Pharmaceuticals, Inc. 2 Gent M. Circulation. 1997; 96 (suppl):
Proton Pump Inhibitor (PPI) Studies
Clinical trial 2. Objective To evaluate efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
Hideki Shimomura, MD* 1 ; Seiji Hokimoto, MD* 2 ; Shuichi Oshima, MD* 3 ; Koichi Nakao, MD* 4 ; Yuji Miyao, MD* 5 ; Hisao Ogawa, MD* 2 ; for the Kumamoto.
Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial Presented at AHA Scientific Sessions Nov. 15, 2000.
Aspirin and Clopidogrel Drug Response in Patients Undergoing Percutaneous Coronary Intervention Published in Journal of the American College of Cardiology.
Clinical Trial Results. org Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary.
Name of the speaker: Germano DiSciascio I have the following potential conflicts of interest to report:  Consulting  Employment in industry  Stockholder.
Can we protect patients undergoing percutaneous coronary intervention better? Beneficial effects of short- and long-term trimetazidine MR therapy in patients.
CARDIOLOGIA INV 1 CAREGGI - FIRENZE Objective To determine whether nonresponsiveness to clopidogrel as revealed by high in vitro residual platelet reactivity.
Efficacy of Ranolazine In Chronic Angina trial
Serial Measurement of Monocyte Chemoattractant Protein-1 After Acute Coronary Syndromes Results From the A to Z Trial JA de Lemos, DA Morrow, SA Wiviott,
Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.
Name of the speaker: Germano DiSciascio I have the following potential conflicts of interest to report:  Consulting  Employment in industry  Stockholder.
PROTECT: What Have We Learned Lesson 2: TMPG is associated with clinical and biomarker outcomes following PCI.
Allen Jeremias, Neal Kleiman, Deborah Nassif, Wen-Hua Hsieh, Michael Pencina, Kelly Maresh, Manish Parikh, Donald Cutlip, Ron Waksman, Steven Goldberg,
ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.
Copyright ©2007 American Heart Association Wiviott SD et al, Circulation 2007 Copyright ©2007 American Heart Association Wiviott SD et al, Circulation.
Giuseppe Biondi Zoccai University of Turin, Turin, Italy METCARDIO, Turin, Italy BMS & Sanofi Aventis Sponsored.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:
Copyright © 2008 Merck & Co., Inc., Whitehouse Station, New Jersey, USA All rights Reserved Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Raltegravir.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Patients With Poor Responsiveness to Thienopyridine.
Adapted from Angiolillo DJ et al. Am J Cardiol. 2006;97: Individual Response Variability to Dual Antiplatelet Therapy in the Steady State Phase of.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Smoking Is Associated With Adverse Clinical Outcomes.
Lack of Evidence of a Clopidogrel – Statin Interaction in the CHARISMA Trial J Am Coll Cardiol 2007;50:291-5 Jacqueline Saw, MD*, Danielle Brennan, MS†,
Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals
Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI
Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin The Randomized, Double-Blind OCLA(Omeprazole CLopidogrel Aspirin)
Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Paul A. Gurbel, MD Director, Sinai Center for Thrombosis Research Sinai Hospital.
The European Society of Cardiology Presented by Dr. Saman Rasoul
The GRAVITAS trial Matthew J. Price MD, FACC, FSCAI
Smoking Paradox for Clopidogrel : : Is It a Myth or Truth?
We Should Tailor Antiplatelet Therapy Based on Platelet Function Testing and Genotyping Paul A. Gurbel Sinai Center for Thrombosis Research Baltimore,
Introduction We have previously reported a significant incidence of clopidogrel resistance in patients post-elective coronary stenting treated with a standard.
Learning Objectives. Learning Objectives Variable Response to Clopidogrel.
RAAS Blockade: Focus on ACEI
Antiplatelet Therapy and Secondary Prevention
Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial
Section 7: Aggressive vs moderate approach to lipid lowering
Nat. Rev. Cardiol. doi: /nrcardio
Impact of Platelet Reactivity Following Clopidogrel Administration
An Analysis of the ACUITY Trial Lincoff AM, JACC Intv 2008;1:639–48
Emerging Data Regarding the Potential Benefits of Early Initiation of Clopidogrel Among ACS Patients C. Michael Gibson, M.S., M.D.
Long Term Clinical Results from the Endeavor Program: 5-Year Follow up
Maintenance of Long-Term Clinical Benefit with
Presentation transcript:

Introduction Clopidogrel is metabolized by P450 (CYP)-isoenzymes: CYP 3A4/5, 1A2, 2B6, 2C9, and 2C19 1 Wide response variability and nonresponsiveness to clopidogrel may be related to functional and genetic variability in CYP isoenzymes. 2 Cigarette smoking induces CYP1A2. 3 Smoking has been associated with an increased benefit of dual antiplatelet therapy on long-term clinical outcomes after PCI. 4 However, there are no laboratory data to support a relation between increased platelet inhibition by clopidogrel in current smokers (CS) as compared to non- smokers (NS). 1. Brandt JT et al. J Thromb Haemost 2007;5: Gurbel PA et al. Thromb Res. 2007;120: Zevin S et al. Clin Pharmacokinet. 1999;36: Saraff KY, et al. J Am Coll Cardiol 2006;36B:Abstract

Objectives The primary objective was to investigate the effect of cigarette smoking on the platelet response to clopidogrel as measured by ADP-induced aggregation using conventional turbidometric aggregometry in platelet rich plasma in patients treated with elective PCI. The secondary objectives were to analyze the relation between clopidogrel response and smoking by using flow cytometry measurements of ADP-induced expression of activation dependent receptors. We hypothesized that 5  M ADP-induced aggregation would be lower in CS following loading and maintenance doses of clopidogrel compared to NS. 1,2 1. Matetzky S, et al. Circulation 2004;109:3171-5, 2. Gurbel PA et al. Circulation 2005;111:1153-9

Methods Patients Platelet function data in 259 current cigarette smokers or non-smokers undergoing elective PCI treated with clopidogrel consecutively enrolled in clinical trials was analyzed. 1,2 104 current smokers (smoking within 2 weeks of PCI) 155 nonsmokers (no smoking within 1 year of PCI). Previous smokers were excluded since the influence of smoking on CYP1A2 activity is highly variable upon smoking cessation and the interval between the last smoking event and enrollment in the study was inconsistent. Patients on chronic clopidogrel therapy prior to PCI(n=120, 75mg/day) were not loaded; 139 clopidogrel naïve patients were loaded with 600 mg immediately after PCI. No patients had been treated with immunosuppressants, antibiotics, or anti-HIV agents that may influence CYP activity within 2 weeks of study. 1. Gurbel PA et al. J Am Coll Cardiol. 2005;46: Gurbel PA et al. Circulation 2005;111:1153-9

Methods Platelet Function Analysis Conventional aggregometry ADP-stimulated total and active GPIIb/IIIa expression by flow cytometry Prior to PCI in all patients In patients loaded with clopidogrel analyses done at hours post-PCI in patients not treated with eptifibatide (n=63), and at  5 days post-PCI in patients treated with eptifibatide (n=76). Statistical Analysis Categorical variables compared by Fischer exact test Continuous variables compared by Student's t-test Logistic regression analysis - evaluate the impact of smoking status, age, body mass index, diabetes, prior MI, family history of CAD, hyperlipidemia, HBP, and statin and other concomitant medications on low post-treatment PA. (MedCalc software (Mariakerke, Belgium)).

Methods Definitions Current smokers smoked  3 cigarettes/day within 2 weeks of PCI Non-smokers: no history of cigarette smoking within 1 year of PCI Low platelet aggregation = lowest quartile of 5μM ADP- induced platelet aggregation measured by light transmittance aggregometry (  29%). Relative inhibition of platelet aggregation (IPA) = [(MPA predose – MPA postdose )/MPA predose ]x 100% MPA = maximum platelet aggregation

Results Patient demographics and procedural characteristics were similar between the groups. Current smokers: greater prevalence of prior MI (46% vs. 23%, p = 0.005) treatment of bifurcation lesions (12% vs. 3%, p = 0.005) Non-smokers: More diabetes (33% vs. 48%, p=0.01) Current smoking was the only variable significantly associated with low post treatment platelet aggregation (odds ratio 2.63, p<0.007)

Results

ADP-Induced Platelet Aggregation * p<0.05 for mean post-treatment platelet aggregation in CS smoking  1/2 pack/day compared to NS and CS smoking <1/2 pack/day.

Conclusions Cigarette smoking influences platelet responsiveness to clopidogrel. The mechanism of the effect deserves further study and may further elucidate the causes of response variability to clopidogrel and the clinical efficacy of clopidogrel in specific patient groups.